Browse studies

Find your next paid study

435 recruiting studies matching your filters

Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS

This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome th…

Acute Myeloid Leukemia With Gene MutationsMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT04493164

Phase 1

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come b…

Colorectal CarcinomaEndometrial CarcinomaMelanoma+19 more

Estimated

~$10 – $7,500

Phase 1

A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Background: Chemokine receptor 4 (CCR4) is a protein that is found on the surface of certain T-cell lymphoma cells and is common in mature T-cell cancers. Whi…

Relapsed and/or Refractory Mature T Cell MalignancyPeripheral T-Cell LymphomaAngioimmunoblastic T-cell Lymphoma+7 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07055477

Phase 1

A Phase 1 Trial of 8-Chloro-Adenosine in Combination With Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of a new 8-chloroadenosine in combination with venetoclax in treating patients with acute myel…

Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT05263284

Phase 1

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recu…

Advanced Solid TumorsRecurrent or Progressive GlioblastomaRelapse or Refractory Myeloid Malignancies

Estimated

~$10 – $8,750

Crossbow Therapeutics, Inc.NCT07779798

Phase 1

A Phase I Study to Determine the Safety and Tolerability of BI 3820768 in Patients With Advanced Relapsed or Refractory Germ Cell Tumours, Endometrial Cancer, or Ovarian Cancer

This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful. People can j…

Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07306559

Feasibility Study of Individualized Treatment Recommendations for Acute Myeloid Leukemia Based on High Throughput Screening and Genomics Data

Every patient responds differently to their cancer treatment, and some treatments work better for some patients more than others. For patients with relapsed, r…

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Estimated

~$10 – $750

City of Hope Medical CenterNCT07613385

Phase 2

A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE)…

Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis

A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC…

UnresectableLocally AdvancedMetastatic Cancers+1 more

Estimated

~$10 – $8,750

Recursion Pharmaceuticals Inc.NCT06678659

Phase 1

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped re…

Relapsed/Refractory Ovarian Carcinoma

Estimated

~$10 – $8,750

TeneoSeven, Inc.NCT07690189

Phase 2

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients …

Hodgkin Lymphoma, AdultRefractory Hodgkin LymphomaClassic Hodgkin Lymphoma

Estimated

~$10 – $7,500

Michael Spinner, MDNCT07021989

Phase 1

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR…

Relapsed/Refractory Myeloma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06066359